Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Notes Payables (2016 - 2025)

Historic Notes Payables for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $36.7 million.

  • Outlook Therapeutics' Notes Payables rose 1924.28% to $36.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $36.7 million, marking a year-over-year increase of 1924.28%. This contributed to the annual value of $29.9 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Outlook Therapeutics reported Notes Payables of $36.7 million as of Q4 2025, which was up 1924.28% from $29.9 million recorded in Q3 2025.
  • Over the past 5 years, Outlook Therapeutics' Notes Payables peaked at $36.7 million during Q4 2025, and registered a low of $12.0 million during Q1 2025.